Logo Logo
Switch Language to German

Kelemen, Katalin; Saft, Leonie; Craig, Fiona E.; Orazi, Attilio; Nakashima, Megan; Wertheim, Gerald B.; George, Tracy I.; Horny, Hans-Peter; King, Rebecca L.; Quintanilla-Martinez, Leticia; Wang, Sa A.; Rimsza, Lisa M. and Reichard, Kaaren K. (2021): Eosinophilia/Hypereosinophilia in the Setting of Reactive and Idiopathic Causes, Well-Defined Myeloid or Lymphoid Leukemias, or Germline Disorders Report of the 2019 Society for Hematopathology/European Association for Haematopathology Workshop. In: American Journal of Clinical Pathology, Vol. 155, No. 2: pp. 179-210

Full text not available from 'Open Access LMU'.


Objectives: To report the findings of the 2019 Society for Hematopathology/European Association for Haematopathologv Workshop within the categories of reactive eosinophilia, hypereosinophilic syndrome (HES), germline disorders with eosinophilia (GDE), and myeloid and lymphoid neoplasms associated with eosinophilia (excluding entities covered by other studies in this series). Methods: The workshop panel reviewed 109 cases, assigned consensus diagnosis, and created diagnosis-specific sessions. Results: The most frequent diagnosis was reactive eosinophilia (35), followed by acute leukemia (24). Myeloproliferative neoplasms (MPNs) received 17 submissions, including chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Myelodysplastic syndrome (MDS), MDS/MPN, and therapy-related myeloid neoplasms received 11, while GDE and HES received 12 and 11 submissions, respectively. Conclusions: Hypereosinophilia and HES are defined by specific clinical and laboratory criteria. Eosinophilia is commonly reactive. An acute leukemic onset with eosinophilia may suggest core-binding factor acute myeloid leukemia, blast phase of chronic myeloid leukemia, BCR-ABL1-positive leukemia, or t(5;14) B-Iymphoblastic leukemia. Eosinophilia is rare in MDS but common in MDSI MPN CEL, NOS is a clinically aggressive MPN with eosinophilia as the dominant feature. Bone marrow morphology and cytogenetic and/or molecular clonality may distinguish CEL from HES. Molecular testing helps to better subclassify myeloid neoplasms with eosinophilia and to identify patients for targeted treatments.

Actions (login required)

View Item View Item